Literature DB >> 6619871

Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum.

M C Olianas, P Onali, N H Neff, E Costa.   

Abstract

We investigated the effect of acetylcholine (ACh) on the activation of adenylate cyclase by dopamine (DA) in a lysed synaptosomal preparation from rat striatum. ACh reduced both basal and the DA-activated adenylate cyclase with an apparent IC50 of approximately 1 microM. From a kinetic analysis it appeared that ACh reduced the Vmax for activation by DA but not the activation constant for DA. For most preparations the Vmax was reduced by 30-40%. The presence of atropine did not affect the activation of the enzyme by DA but it blocked the inhibition by ACh. Following 6-hydroxydopamine lesion of the nigrostriatal pathway, the enzyme became supersensitive to activation by DA and also more sensitive to inhibition by ACh. Inhibition of adenylate cyclase by ACh appeared to be rather specific for activation by DA, as ACh had no effect on activation of adenylate cyclase by the adenosine analogue N6-(L-2-phenylisopropyl)adenosine. These results indicate that some striatal muscarinic and dopaminergic receptors are probably coupled to the same adenylate cyclase domain. Moreover, they suggest a biochemical model for the dynamic balance of cholinergic and dopaminergic neurons that innervate the striatum.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6619871     DOI: 10.1111/j.1471-4159.1983.tb00834.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Positive coupling of cholinergic muscarinic receptors to adenylate cyclase activity in membranes of rat olfactory bulb.

Authors:  P Onali; M C Olianas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

2.  Dopamine D-2 receptors inhibit D-1 stimulated cyclic AMP accumulation in striatum but not limbic forebrain.

Authors:  E Kelly; S R Nahorski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

3.  The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.

Authors:  Yotam Sagi; Noam Driguès; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

4.  Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics.

Authors:  A S Undie; E Friedman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Atrial muscarinic receptors: effect of Triton X-100 on guanine nucleotide and ammonium ion modulation.

Authors:  J S Aguilar; E De Robertis
Journal:  Neurochem Res       Date:  1986-03       Impact factor: 3.996

6.  Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor-stimulated adenylyl cyclase activity by cholinoceptor antagonist used to treat Parkinson's disease.

Authors:  M C Olianas; P Onali
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

7.  Pertussis vaccine reduces agonist binding to the rat heart muscarinic receptor and its guanine nucleotide modulation.

Authors:  J S Aguilar; M I Fonseca; E De Robertis
Journal:  Neurochem Res       Date:  1986-05       Impact factor: 3.996

8.  Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3).

Authors:  M C Olianas; A Adem; E Karlsson; P Onali
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.